--------------------------
OMB APPROVAL
-------------------------- --------------------------
OMB Number: 3235-0287
Form 4 --------------------------
Expires: January 31, 2005
-------------------------- --------------------------
Estimated average burden
hours per response...0.5
--------------------------
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935
or Section 30(h) of the Investment Company Act of 1940
/ / Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
(Print or Type Responses)
1. Name and Address of Reporting Person*
Dixon Rosina B.
(Last) (First) (Middle)
c/o Enzon Pharmaceuticals, Inc.
685 Route 202/206
(Street)
Bridgewater New Jersey 08807
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ENZON PHARMACEUTICALS, INC. (ENZN)
3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)
4. Statement for Month/Year
March 31, 2003
5. If Amendment, Date of Original (Month/Day/Year)
6. Relationship of Reporting Person(s) to Issuer (Check all applicable)
/X/ Director / / 10% Owner
/ / Officer (give title below) / / Other (specify below)
7. Individual or Joint/Group Reporting (Check Applicable Line)
/X/ Form filed by One Reporting Person
/ / Form filed by More than One Reporting Person
Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
5. Amount
of Secu-
rities
Bene-
ficially
2A. Deemed 4. Securities Acquired (A) Owned
2. Trans- Execution 3. Trans- or Disposed of (D) Following
action Date, action (Instr. 3, 4 and 5) Reported
Date if any Code ----------------------------- Trans-
(Month/ (Month/ (Instr. 8) (A) action(s)
1. Title of Security Day/ Day/ ------------- Amount or Price (Instr.
(Instr. 3) Year) Year) Code V (D) 3 and 4)
----------------------------- ---------- ------------ ------ ----- ------------ --- ---------- -----------
Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
6. Ownership
Form:
Direct 7. Nature of
(D) or Indirect
Indirect Beneficial
1. Title of Security (I) Ownership
(Instr. 3) (Instr. 4) (Instr. 4)
----------------------------- ------------- --------------
Table II--Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
3A. Deemed
2. Conver- Execu- 5. Number of Deriv-
sion or 3. Trans- tion ative Securities
Exercise action Date, 4. Transac- Acquired (A) or
Price of Date if any tion Code Disposed of (D)
Deriv- (Month/ (Month/ (Instr. 8) (Instr. 3, 4, and 5)
1. Title of Derivative Security ative Day/ Day/ ------------- --------------------------
(Instr. 3) Security Year) Year) Code V (A) (D)
---------------------------------------- ----------- ---------- ------------ ------ ----- ------------ ------------
Common Stock Right(1) 1 - for - 3/31/03 A 485
9. Number of
Derivative
Securities
6. Date Exercisable Benefi-
and Expiration Date 7. Title and Amount of Underlying cially
(Month/Day/Year) Securities (Instr. 3 and 4) Owned
---------------------- ---------------------------------------- 8. Price of Following
Date Amount or Derivative Reported
1. Title of Derivative Exercis- Expiration Title Number of Security Transaction(s)
Security (Instr. 3) able Date Shares (Instr. 5) (Instr. 4)
--------------------------- ---------- ---------- --------------------------- ----------- ------------- -----------------
Common Stock Right(1) See See Common 485 485
Footnote Footnote Stock
(1) (1)
10. Ownership
Form of
Derivative
Securities: 11. Nature of
Direct (D) Indirect
or Indirect Beneficial
1. Title of Derivative (I) Ownership
Security (Instr. 3) (Instr. 4) (Instr. 4)
--------------------------- -------------- ---------------
Common Stock Right(1) D
Explanation of Responses:
(1) Securities granted by Enzon Pharmaceuticals, Inc. pursuant to Enzon's
2001 Incentive Stock Plan as compensation for service as an Independent Director
during the quarter ended March 31, 2003 and qualified under Rule 16b-3(d). The
value of the compensation was $5,500. In the spring of 2004, each Common Stock
right will be exchanged for one share of Common Stock; provided, however, Ms.
Dixon will be entitled to elect to receive cash for up to 50% of these rights,
with the price per right being $11.35, the fair market value of Enzon's common
stock on March 31, 2003.
/s/ Kenneth J. Zuerblis 4/02/03
--------------------------------------- --------------------------
**Signature of Reporting Person Date
Attorney-in -fact
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the form is filed by more than one reporting person, see instruction
4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If
space is insufficient, see Instruction 6 for procedure.